NEW YORK (360Dx) – Immunodiagnostics firm Singulex announced today that it has formed a strategic collaboration with Qiagen to develop companion diagnostics.
Under the terms of the deal, Qiagen will combine Singulex's single-molecule counting (SMC) technology with its own molecular testing services to develop companion diagnostics. Qiagen will also have access to Singulex's CLIA lab. The companies aim to collaborate in a range of disease applications, Singulex said.
Additional terms were not disclosed.